WuXi AppTec Co Ltd traded at 70.80 this Wednesday September 28th, decreasing 1.44 or 1.99 percent since the previous trading session. Looking back, over the last four weeks, WuXi AppTec Co Ltd lost 20.02 percent. Over the last 12 months, its price fell by 52.83 percent. Looking ahead, we forecast WuXi AppTec Co Ltd to be priced at 67.47 by the end of this quarter and at 61.94 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Cspc Pharmaceutical 7.37 0 0% -21.85%
Sino Biopharmaceutical Ltd 3.61 -0.13 -3.48% -42.79%
Sh Fosun Pharma 29.56 -0.89 -2.92% -43.21%
Jiangsu Hengrui Me. 33.47 -0.18 -0.53% -32.95%
Sh Pharmaceutical 16.49 -0.06 -0.36% -13.26%

WuXi AppTec Co Ltd
WuXi AppTec Co., Ltd. is a China-based investment holding company principally engaged in the provision of new drug research and development (R&D), production and supporting services, as well as related technology platform services. The Company is mainly engaged in the discovery, development and production of small molecule drugs, cell therapies and gene therapies, as well as providing testing services for medical devices. The Company mainly conducts its businesses through four segments, including China-based Laboratory Services segment, Contract Manufacturing organization/contract development and manufacturing organization services (CMO/CDMO services) segment, US-based Laboratory Services segment and Clinical Research segment.